TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE22.3600
- TODAY'S CHANGE (%)0.1700 (0.7661%)
- Bid / Lots22.3400/ 1
- Ask / Lots22.3800/ 3
- Open / Previous Close22.5000 / 22.1900
- Day Range
- 52 Week Range
- Volume208,007
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 15440 | 22.695 |
| 09:34 ET | 9806 | 22.54 |
| 09:36 ET | 17343 | 22.52 |
| 09:38 ET | 11554 | 22.625 |
| 09:39 ET | 4339 | 22.641 |
| 09:41 ET | 4631 | 22.6 |
| 09:43 ET | 5015 | 22.59 |
| 09:45 ET | 4352 | 22.61 |
| 09:48 ET | 3000 | 22.605 |
| 09:50 ET | 2930 | 22.55 |
| 09:52 ET | 4140 | 22.56 |
| 09:54 ET | 428 | 22.54 |
| 09:56 ET | 6623 | 22.41 |
| 09:57 ET | 4460 | 22.4101 |
| 09:59 ET | 7200 | 22.35 |
| 10:01 ET | 6083 | 22.42 |
| 10:03 ET | 2048 | 22.36 |
| 10:06 ET | 3901 | 22.35 |
| 10:08 ET | 10452 | 22.38 |
| 10:10 ET | 6664 | 22.27 |
| 10:12 ET | 2931 | 22.19 |
| 10:14 ET | 14903 | 22.195 |
| 10:15 ET | 20435 | 22.21 |
| 10:17 ET | 3317 | 22.285 |
| 10:19 ET | 1449 | 22.32 |
| 10:21 ET | 4000 | 22.36 |
Sep 18, 2024
DJ TG Therapeutics Price Target Maintained With a $49.00/Share by HC Wainwright & Co., from 1:12PM ET on Wednesday Sep 18, 2024 by Dow Jones
1:12PM ET on Wednesday Sep 18, 2024 by Dow JonesNew BRIUMVI(R) (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis, from 7:15AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:15AM ET on Wednesday Sep 18, 2024 by Dow JonesNew Data for BRIUMVI(R) (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment, from 7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 6, 2024
Sep 5, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 3.4B | 37.3x | --- |
Twist Bioscience Corp | 2.5B | -11.4x | --- |
Apellis Pharmaceuticals Inc | 3.4B | -10.2x | --- |
Arrowhead Pharmaceuticals Inc | 2.3B | -4.1x | --- |
Zai Lab Ltd | 2.5B | -8.4x | --- |
Alvotech SA | 3.7B | -4.6x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $346.7M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $0.60 |
Book Value | $1.06 |
P/E Ratio | 37.3x |
Price/Sales (TTM) | 9.9 |
Price/Cash Flow (TTM) | 35.8x |
Operating Margin | 29.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
